Recombinetics

Recombinetics was a St. Paul, Minnesota-based bio-engineering company founded in 2008. Its work focused on applying genetic engineering and gene-editing techniques to animal agriculture and biomedical research. Rather than operating as a conventional consumer-facing brand, Recombinetics functioned primarily as a research and technology company whose value proposition centered on modifying animal genetics to address agricultural, veterinary, and medical objectives. The company became particularly known for developing genetically engineered cattle that did not grow horns. Hornless, or polled, cattle could potentially reduce the need for dehorning, a management procedure used in parts of the cattle industry to limit injuries among animals and handlers. Recombinetics also pursued research involving pigs as potential sources of human organs and tissues, reflecting the broader field of xenotransplantation and the use of genetically modified animals in biomedical research. Recombinetics attracted more than $34 million from private investors, according to the referenced account, and was led by Mark Platt as chief executive officer. Its work brought together agricultural biotechnology, livestock breeding, gene editing, and translational biomedical research. The company’s activities also placed it within contentious regulatory and ethical debates concerning genetically modified animals, animal welfare, food production, biosecurity, and the evidentiary standards required before modified animals can enter the food or medical supply chain. The hornless-cattle program became the subject of significant scrutiny after researchers identified bacterial DNA associated with antibiotic resistance in the animals’ genomes. This genetic material had not been intended as part of the desired hornless trait. The finding challenged earlier assurances that the modification had produced no effects beyond the absence of horns and raised questions about genetic characterization, regulatory review, and the safety of using such animals in agriculture. The referenced material states that approval by the United States Food and Drug Administration was considered unlikely and that a number of affected animals were subsequently killed and their bodies burned. In November 2024, Recombinetics filed for Chapter 11 bankruptcy protection. The company was subsequently acquired by Trans Ova Genetics for $4.1 million. This transaction marked the end of Recombinetics as an independent operating company, although the acquisition potentially preserved or transferred some of its technology, intellectual property, research programs, or other assets. Details about the post-acquisition structure and the continued commercial use of its programs are not established by the supplied sources.

Recombinetics was established in 2008 in St. Paul, Minnesota, as an animal biotechnology and bio-engineering company. Its research program centered on the use of genetic engineering and gene editing in animals. The company targeted two related but distinct areas: agricultural applications intended to alter useful livestock traits, and biomedical applications involving animals as potential sources of organs or tissues for human medicine. One of Recombinetics’ best-known projects involved cattle engineered not to grow horns. Cattle are often dehorned or disbudded to reduce the risk of injuries, but these procedures can create animal-welfare and management concerns. A genetically hornless animal could theoretically remove the need for that intervention. Recombinetics’ work therefore attracted interest as a possible application of gene editing to improve livestock handling and production practices. The cattle research later generated a major scientific and regulatory controversy. Investigators found that the animals contained bacterial DNA associated with antibiotic resistance in addition to the intended genetic change. The discovery indicated that the editing process had introduced unintended material and undermined claims that the animals had no alterations other than the absence of horns. Because the finding involved a potentially important resistance marker, it raised questions about the completeness of genome analysis, the reliability of safety claims, and whether the animals could be accepted for food production. The supplied reference states that FDA approval was unlikely and that several affected animals were killed and their remains burned. Recombinetics also worked on genetically modified pigs for biomedical research, including the possibility of growing human organs and tissues in pigs. This work belongs to the broader field of xenotransplantation, in which animal organs or tissues are investigated as possible substitutes for human donor material. Such programs require extensive genetic modification and testing because of immune rejection, infectious-disease transmission, physiological compatibility, and ethical concerns. The company raised more than $34 million from private investors and was led by Mark Platt as CEO. Its financial backing supported research in a technically complex field, but the company’s projects also depended on regulatory acceptance and the ability to translate laboratory results into commercially viable agricultural or medical products. In November 2024, Recombinetics filed for Chapter 11 bankruptcy protection. It was then acquired by Trans Ova Genetics for $4.1 million. The acquisition transferred the company’s business or assets to Trans Ova Genetics, although the supplied material does not specify which intellectual property, personnel, facilities, or research programs continued after the transaction. Recombinetics should therefore be treated as a defunct independent company, with any surviving technology considered part of the acquiring company’s operations unless documented otherwise.

• 2024

  Chapter 11 filing and acquisition

  [1]Recombineticsen.wikipedia.org

  Recombinetics filed for Chapter 11 protection in November and was acquired by Trans Ova Genetics for $4.1 million.

• 2008

  Company founded

  [1]Recombineticsen.wikipedia.org

  Recombinetics was founded in St. Paul, Minnesota, to develop bio-engineering and gene-editing applications for animal agriculture and biomedical research.

• Development of gene-edited hornless cattle

  [1]Recombineticsen.wikipedia.org

  The company developed genetically engineered cattle that did not grow horns, aiming to provide an alternative to conventional dehorning practices.

• Expansion into biomedical animal research

  [1]Recombineticsen.wikipedia.org

  Recombinetics pursued research involving genetically modified pigs as potential hosts for growing human organs and tissues.

A research-oriented animal biotechnology company applying gene editing to livestock production and biomedical research, with a focus on traits intended to improve animal management and on genetically modified animals for potential medical applications.

• Agricultural biotechnology

  Gene-edited hornless cattle

  Recombinetics developed cattle genetically modified so they would not grow horns. The intended agricultural benefit was to reduce or eliminate the need for dehorning, a procedure used to limit injuries in cattle management. The program became controversial after bacterial DNA associated with antibiotic resistance was found in the animals, creating regulatory and safety concerns beyond the intended hornless trait.

• Biomedical biotechnology

  Genetically modified pigs for biomedical research

  The company worked on genetically modified pigs as potential biological sources of human organs and tissues. This research was directed toward biomedical applications related to xenotransplantation, a field that seeks to address shortages of human donor organs. The supplied sources do not establish that Recombinetics brought a pig-derived organ or tissue product to clinical use.

• Unintended bacterial DNA in hornless cattle

  Analysis of Recombinetics’ genetically engineered hornless cattle found bacterial DNA associated with antibiotic resistance. The finding raised concerns about unintended genetic changes, the accuracy of prior safety claims, and the possibility of regulatory approval. The referenced account states that some of the affected animals were killed and their bodies burned.

  Source

Read more

• 2024

  File for Chapter 11 protectionOther

  Background

  Recombinetics entered a formal restructuring process after operating as a privately financed animal-biotechnology company.

  Action taken

  The company filed for Chapter 11 bankruptcy protection in November 2024.

  Aftermath

  Trans Ova Genetics acquired Recombinetics for $4.1 million, ending the company’s independent status.

  Source

• 2024

  Acquisition by Trans Ova GeneticsM&A

  Background

  After Recombinetics filed for Chapter 11, its business or assets were offered for acquisition.

  Action taken

  Trans Ova Genetics acquired Recombinetics for $4.1 million.

  Aftermath

  Recombinetics ceased to operate as an independent company. The supplied sources do not identify which programs or assets continued under Trans Ova Genetics.

  Acquisition price. $4.1 million (2024)

  Source

• 2021.01.12

  Reported2021.01.12

  Recombinetics and AstraZeneca announce NF1 research collaboration[2]Recombinetics与阿斯利康宣布开展NF1研究合作prnewswire.com

  Recombinetics announced a research collaboration with AstraZeneca to assess selumetinib for cutaneous neurofibromas using Surrogen's NF1 preclinical platform.

Read more

1. 1Recombineticsen.wikipedia.org
2. 2Recombinetics与阿斯利康宣布开展NF1研究合作prnewswire.com